With the continuous improvement of the treatment level in the medical field, the treatment of ophthalmic diseases has developed rapidly in recent years, but most of the treatment methods still cannot improve the vision of patients. The emergence of vascular endothelial growth factor inhibitors is expected to improve the vision of patients, such drugs mainly include bevacizumab, ranibizumab, aflibercept, and conbercept. Aflibercept is a fusion homodimeric glycoprotein produced by Chinese hamster ovary K1 cells by recombinant DNA technology. At present, aflibercept and conbercept, as the two newest anti-VEGF drugs, belong to VEGF recombinant decoy receptors, have similar molecular mechanisms of action and pharmacological properties, and have high specificity and affinity for VEGF. It is widely used in the treatment of ophthalmic diseases and has achieved good curative effect, providing a better treatment plan for patients whose vision is seriously threatened in China.

1. Limitations of Aflibercept

During the clinical follow-up observation, it was found that intravitreal injection of aflibercept in the treatment of ophthalmic related diseases can cause subconjunctival hemorrhage, intraocular infection, eye pain, increased intraocular pressure, cataract, posterior vitreous detachment and even retina In addition to adverse reactions such as detachment, the current follow-up period for the treatment of ophthalmology-related diseases with aflibercept is short, and the number of studies is limited. A large number of clinical trials and long-term follow-up are needed to further evaluate whether repeated injections of aflibercept or increased doses of injections will cause adverse reactions. The occurrence of ocular adverse events and the increased risk of retinal toxicity should increase the sample size to compare the efficacy, safety and economics of aflibercept and other anti-VEGF drugs in the treatment of ophthalmic diseases.

2. Advantages and application prospects of Aflibercept

Aflibercept has the following advantages:

(1) The drug has a long half-life, can widely bind to most VEGFRs with high affinity, and reduces the number of injections and the risk of infection;

(2) Reduce macular edema, reduce edema area, maintain and improve macular structure;

(3) Significantly improve the visual quality of patients;

(4) Promote and restore the formation of physiological new blood vessels in the retina.

Aflibercept brings a new treatment option for fundus neovascularization lesions. As far as the current clinical application is concerned, aflibercept has achieved good results in the treatment of ophthalmic diseases in the short term. Quality of life in visually impaired patients with organic eye disease.

Minbiotch Co., Ltd. is committed to the production of biomedicine and a variety of high-end generic drugs and innovative drugs. It is the supplier of Aflibercept. Welcome to visit our website.